| Title |
The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders
|
|---|---|
| Published in |
Psychopharmacology, August 2013
|
| DOI | 10.1007/s00213-013-3232-4 |
| Pubmed ID | |
| Authors |
Maddalena Mereu, Antonello Bonci, Amy Hauck Newman, Gianluigi Tanda |
| Abstract |
Modafinil (MOD) and its R-enantiomer (R-MOD) are approved medications for narcolepsy and other sleep disorders. They have also been used, off-label, as cognitive enhancers in populations of patients with mental disorders, including substance abusers that demonstrate impaired cognitive function. A debated nonmedical use of MOD in healthy individuals to improve intellectual performance is raising questions about its potential abuse liability in this population. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 215 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 2% |
| Brazil | 3 | 1% |
| United Kingdom | 2 | <1% |
| Kenya | 1 | <1% |
| India | 1 | <1% |
| Portugal | 1 | <1% |
| Canada | 1 | <1% |
| South Africa | 1 | <1% |
| Unknown | 201 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 37 | 17% |
| Student > Master | 29 | 13% |
| Researcher | 27 | 13% |
| Student > Ph. D. Student | 25 | 12% |
| Student > Postgraduate | 12 | 6% |
| Other | 37 | 17% |
| Unknown | 48 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 39 | 18% |
| Agricultural and Biological Sciences | 26 | 12% |
| Psychology | 26 | 12% |
| Neuroscience | 20 | 9% |
| Biochemistry, Genetics and Molecular Biology | 12 | 6% |
| Other | 39 | 18% |
| Unknown | 53 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 40. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 October 2023.
All research outputs
#1,012,646
of 25,243,120 outputs
Outputs from Psychopharmacology
#261
of 5,640 outputs
Outputs of similar age
#8,289
of 204,589 outputs
Outputs of similar age from Psychopharmacology
#5
of 53 outputs
Altmetric has tracked 25,243,120 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,640 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.5. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 204,589 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 53 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.